Patrick Durez
About
In The Last Decade
Patrick Durez
192 papers receiving 7.0k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Rheumatology 5.1k
- Hematology 2.4k
- Immunology 2.2k
- Genetics 1.3k
- Pathology and Forensic Medicine 969
Countries citing papers authored by Patrick Durez
This map shows the geographic impact of Patrick Durez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Durez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Durez more than expected).
Fields of papers citing papers by Patrick Durez
This network shows the impact of papers produced by Patrick Durez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Durez. The network helps show where Patrick Durez may publish in the future.
Co-authorship network of co-authors of Patrick Durez
This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Durez. A scholar is included among the top collaborators of Patrick Durez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Durez. Patrick Durez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 1 | |
| 4 | 7 | |
| 5 | 3 | |
| 6 | 4 | |
| 7 | Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic | 0 |
| 8 | A twelve-week exploratory phase II trial of GLPG0259 versus placebo in patients with active rheumatoid arthritis and inadequate response to methotrexate | 1 |
| 9 | A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: the Be-Raise study | 1 |
| 10 | Feasibility of a molecular diagnosis of arthritis based on the iIdentification of specific transcriptomic profiles in knee synovial biopsies | 3 |
| 11 | Reduced Radiographic Progression in Patients with Early Rheumatoid Arthritis (RA) Treated with Abatacept plus Methotrexate Compared to Methotrexate Alone: 24 Month Outcomes | 2 |
| 12 | Disease Remission is Achieved Within Two Years In Over Half of Methotrexate Naive Patients with Early Erosive Rheumatoid Arthritis (RA) Treated with Abatacept Plus MTX: Results from The AGREE Trial | 5 |
| 13 | Clinical remission, radiographic non-progression, and normalized function with the combination of etanercept and methotrexate in the treatment of early active rheumatoid arthritis: 1-year results of the COMET trial | 1 |
| 14 | Improvement in DAS28 response through one-year of golimumab treatment in patients with active RA despite treatment with methotrexate: A phase II, randomized, double blind, placebo controlled, dose ranging trial | 2 |
| 15 | Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition. | 1 |
| 16 | Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Attrition and long-term clinical effect | 1 |
| 17 | L’avant pied rhumatoïde | 0 |
| 18 | The effect of infliximab on rheumatoid nodules: A histopathological study | 2 |
| 19 | Safety of combination of methotrexate (MTX) and infliximab (IFX) in a large Belgian observational patient cohort with refractory rheumatoid arthritis. | 2 |
| 20 | Autologous stem cell transplantation in rheumatoid arthritis | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.